SCHEMBL13289489

SCHEMBL13289489

Bc1cnn2c(NCCCCNS(=O)(=O)c3ccsc3C(=O)OC)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.39
▸ CDK2 P24941 3/20 0.38
▸ MAPT P10636 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ NOD2 Q9HC29 1/20 0.35
▸ CCR2 P41597 1/20 0.35
▸ EDNRA P25101 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ TAS2R8 Q9NYW2 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289124 0.96 GSK3B (0.40) GSK3BCDK2MAPTALDH1A1GAA
SCHEMBL13121167 0.91 GSK3B (0.49) GSK3BCDK2MAPTALDH1A1GAA
SCHEMBL13121089 0.90 GSK3B (0.49) GSK3BCDK2MAPTALDH1A1GAA
SCHEMBL13289147 0.89 GSK3B (0.38) GSK3BCDK2MAPTNPSR1LMNA
SCHEMBL13289007 0.88 GSK3B (0.41) GSK3BCDK2MAPT
SCHEMBL13288959 0.88 CDK2 (0.43) GSK3BCDK2MAPTALDH1A1GAA
SCHEMBL13121296 0.87 GSK3B (0.51) GSK3BCDK2MAPTALDH1A1GAA
SCHEMBL13289301 0.84 CDK2 (0.46) GSK3BCDK2MAPTALDH1A1NPSR1
SCHEMBL13289089 0.83 CDK2 (0.44) GSK3BCDK2MAPTALDH1A1NPSR1
SCHEMBL13288981 0.83 CDK2 (0.46) GSK3BCDK2MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback